latest news releases from the newsroom
Provalis awarded GBP1.6m from Dimethaid Arbitration
DEESIDE, Flintshire, U.K., Dec. 16, 2003 (PRIMEZONE) -- Provalis plc (LSE: PRO; NASDAQ: PVLS), the Medical Diagnostics and Pharmaceuticals Group, announces that the arbitration it commenced against Dimethaid International Inc. following Dimethaid's termination of the Pennsaid distribution agreement has been decided in Provalis' favour, and that as a result Provalis has been awarded the compensatory sum of just over GBP1.2m, together with costs and interest of approximately GBP360k.
Saab signs further Meteor contract worth MSEK 485
LINKOPING, Sweden, Dec. 16, 2003 (PRIMEZONE) -- As a result of its involvement, announced in January 2003, in the Meteor European air-to-air missile project, Saab Bofors Dynamics has now received a further development order from the main contractor MBDA UK, worth MSEK 485.
Altima AB Listed at Stockholmsborsen
STOCKHOLM, Sweden, Dec. 16, 2003 (PRIMEZONE) -- Today Altima AB is listed at Stockholmsborsen. Altima's shares will be listed on the O-list, after All Cards Service Center AB. "We greet Altima welcome to Stockholmsborsen," says Kerstin Hessius, President at Stockholmsborsen and Deputy Head of HEX Integrated Markets. Altima is a machinery-rental company that is active in the Nordic region and the Baltic countries. The company's operations are currently represented at about 60 customer centers in Sweden, Norway, Denmark, Finland, Estonia, Latvia, Lithuania and St. Petersburg.
Trigen's Novel Oral Anti-Coagulant, TGN 167, Successfully Completes Phase I Study
LONDON, Dec. 16, 2003 (PRIMEZONE) -- Trigen Ltd today announced the successful completion of a Phase I dose escalation study for its highly selective oral direct thrombin inhibitor (DTI), TGN 167, which is being developed for the prevention and treatment of thrombosis. Trigen is developing TGN 167 for safe, effective, predictable and convenient anti-coagulation for chronic out-patient use.
Bayer Healthcare and Galapagos in Target Discovery Collaboration
MECHELEN, Belgium, Dec. 16, 2003 (PRIMEZONE) -- Galapagos Genomics today announced a target discovery collaboration with Bayer HealthCare AG. Within the partnership, the Companies will collaborate to discover and validate novel drug targets for Bayer's disease areas. Galapagos will use its disease biology expertise in combination with its SilenceSelect(tm) and FLeXSelect(tm) target discovery collections to identify and validate drugable targets. Under the terms of the agreement, Bayer HealthCare has the exclusive right to select validated targets for drug development in return for upfront payments, research funding and milestones. Further financial terms were not disclosed.
Atna Resources Ltd.
DeLancey Resigns From Atna Board
VANCOUVER, British Columbia, Dec. 15, 2003 (PRIMEZONE) -- Atna Resources Ltd. (TSE:ATN) announces the resignation of Peter DeLancey from its Board of Directors, to take effect December 15. Mr. DeLancey is stepping down for health reasons. Peter has served Atna shareholders with distinction as President and Director from 1989 to 2000, as Chairman of the Board from 2000 to 2002, and since then as a Director and Chief Geologist. During his tenure with the company, he led its exploration team to its most important success to date: the discovery of the Wolverine massive sulphide zinc -- silver -- copper -- gold -- lead deposit in the Yukon, in which the company continues to retain a 39.5% interest.